维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Lissandra"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours显示文摘	M.S. Aapro J. Bohlius D.A. Cameron Lissandra Dal Lago J. Peter Donnelly N. Kearney G.H. Lyman R. Pettengell V.C. Tjan-Heijnen J. Walewski Damien C. Weber C. Zielinski	2010	European Journal of Cancer2010，，1：	1
	2	Molecular-targeted therapies; lessons from years of clinical development显示文摘	GUSTAVO I LISSANDRA D L AHMAD A	2008	Cancer Treat Rev2008，34，1：	1
	3	Current perspec- tive of epothiones in breast cancer显示文摘	FATIMA C EUANDRO A LISSANDRA DL	2008	Eur J Cnacer2008，44，2：	1
	4	Use of trastuzumab for the treat- ment of early stage breast cancer 显示文摘	Sofia B Lissandra dL Chantal B	2006	Expet Rev Anticancer Ther2006，6，8：	1
	5	Glucans from the Caripia montagnei mushroom present anti-inflammatory activity显示文摘	Lissandra S Q Arna K M C Allisson J G C		0，，10：	1
	6	Correction for chromo- some - 17 is critical for the determination of true Her - 2/neu gene amplification status in breast cancer 显示文摘	Lissandra DL Virginie D Christine D	2006	Mol Cancer Ther2006，5，10：	1
	7	Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future显示文摘Febrile neutropenia(FN) is responsible for significant morbidity and mortality. It can also be the reason for delaying or changing potentially effective treatments and generates substantial costs. It has been recognized for more than 50 years that empirical administration of broad spectrum antibiotics to patients with FN was associated with much improved outcomes; that has become a paradigm of management. Increase in the incidence of microorganisms resistant to many antibiotics represents a challenge for the empirical antimicrobial treatment and is a reason why antibiotics should not be used for the prevention of neutropenia. Prevention of neutropenia is best performed with the use of granulocyte colonystimulating factors(G-CSFs). Prophylactic administration of G-CSFs significantly reduces the risk of developing FN and consequently the complications linked to that condition; moreover, the administration of G-CSF is associated with few complications, most of which are not severe. The most common reason for not using G-CSF as a prophylaxis of FN is the relatively high cost. If FN occurs, in spite of prophylaxis, empirical therapy with broad spectrum antibiotics is mandatory. However it should be adjusted to the risk of complications as established by reliable predictive instruments such as the Multinational Association for Supportive Care in Cancer. Patients predicted at a low level of risk of serious complications, can generally be treated with orally administered antibiotics and as out-patients. Patients with a high risk of complications should be hospitalized and treated intravenously. A short period of time between the onset of FN and beginning of empirical therapy is crucial in those patients. Persisting fever in spite of antimicrobial therapy in neutropenic patients requires a special diagnostic attention, since invasive fungal infection is a possible cause for it and might require the use of empirical antifungal therapy.	Jean Klastersky Marianne Paesmans Michel Aoun Aspasia Georgala Angela Loizidou Yassine Lalami Lissandra Dal Lago	2016	World Journal of Clinical Infectious Diseases2016，6，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费